

Kidney Cancer (Renal Cell Carcinoma) Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ Pathology: _____

Stage: 0 I II III IV Recurrent

Line of Treatment: Neoadjuvant/Pre-Op Adjuvant/Post-Op First Line Second Line Third Line Third Line +

ECOG Performance Status: 0 1 2 3 4

Biomarker:

Prior therapy: _____

Renal cancer risk: Poor risk Intermediate risk Good risk

Metastatic Disease | First Line of Therapy (1st Line)

High dose intravenous (IV) interleukin-2 (IL2, Proleukin) (**clear cell only**)

Pazopanib (Votrient)

Sunitinib (Sutent)

Metastatic Disease | First Line of Therapy (1st Line) | Poor Prognosis* or Non-Clear Cell Histology

Temsirolimus (Torisel)

Metastatic Disease | Second or Subsequent Lines of Therapy (2nd Line+) | Clear Cell Carcinoma

Nivolumab (Opdivo)

*Poor prognosis patients have 3 or more of the following predictors of short survival:

- LDH greater than 1.5 x normal
- Hemoglobin less than normal (anemia)
- Corrected serum calcium (Ca) greater than 10 ng/dL
- Less than 1 year from diagnosis to the start of systemic therapy
- Karnofsky performance status \leq 70 (Unable to carry on normal activity or do active work, but able to perform self-care)
- 2 or more sites of organ metastases

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

